Back to Authors

Hurn, Patricia D.

Mayo Clinic

University of Michigan

Citations 2

Considering sex as a biological variable in preclinical research
Miller, Leah, Marks, Cheryl L., Hurn, Patricia D., Woodruff, Teresa K. , Sohrabji, Farida , Schiebinger, Londa , Wetherington, Cora Lee, Makris, Susan L. , Arnold, Arthur P. , Einstein, Gillian , Miller, Virginia M. , Sandberg, Kathryn , Maier, Susan, Cornelison, Terri L., Becker, Jill B. , Chen, Wei‐Jung , McCarthy, Margaret M. , Clayton, Janine A. , Schiebinger, Londa

The FASEB Journal | September 28, 2016 | Volume: 31 | Issue: 1 | Pages: 29-34

10.1096/fj.201600781r Get It

In June 2015, the National Institutes of Health (NIH) released a Guide notice (NOT‐OD‐15–102) that highlighted the expectation of the NIH that the possible role of sex as a biologic variable be factored into research design, analyses, and reporting of vertebrate animal and human studies. Anticipating these guidelines, the NIH Office of Research on Women's Health, in October 2014, convened key stakeholders to discuss methods and techniques for integrating sex as a biologic variable in preclinical research. The workshop focused on practical methods, experimental design, and approaches to statistical analyses in the use of both male and female animals, cells, and tissues in preclinical research. Workshop participants also considered gender as a modifier of biology. This article builds on the workshop and is meant as a guide to preclinical investigators as they consider methods and techniques for inclusion of both sexes in preclinical research and is not intended to prescribe exhaustive/specific approaches for compliance with the new NIH policy.—Miller, L. R., Marks, C., Becker, J.B., Hurn, P.D., Chen, W.‐J., Woodruff, T., McCarthy, M.M., Sohrabji, F., Schiebinger, L., Wetherington, C.L., Makris, S., Arnold, A. P., Einstein, G., Miller, V. M., Sandberg, K., Maier, S., Cornelison, T. L., Clayton, J. A. Considering sex as a biological variable in preclinical research. FASEB J. 31, 29–34 (2017) www.fasebj.org
Advancing the Study of Stroke in Women
Hurn, Patricia D., Colton, Carol A. , Miller, Virginia M. , Zoppo, Gregory del, Elkind, Mitchell S.V. , Stern, Barney J. , Herrington, David M. , Ford-Lynch, Gwendolyn, Gorelick, Philip B. , James, Allison , Brown, Candice M. , Choi, Emily W. , Bray, Paul F. , Newby, L. Kristin , Simpkins, James, Bushnell, Cheryl , Goldstein, Larry B. , James, Andra H

Stroke | July 21, 2006 | Volume: 37 | Issue: 9 | Pages: 2387-2399

10.1161/01.str.0000236053.37695.15 Get It

Background and Purpose— Women have poorer outcomes from stroke than men. Women also have risk factors that are unique, including pregnancy and hormone therapy. Hormone therapy for postmenopausal replacement increased the risk of ischemic stroke according to results of the Women’s Health Initiative clinical trials. Based on the current understanding of the mechanisms of action of estrogen, the reasons for this increased risk are uncertain. One method to better understand the reasons for this increased risk is to re-evaluate estrogen’s role in the neurovascular unit, simplistically comprised of the neurons, glia, and endothelial cells, as well as the processes of inflammation, and hemostasis/thrombosis. Besides the role of estrogen there are many gaps of knowledge about issues specific to women and stroke. Summary of Review— A multidisciplinary workshop was held in August 2005 to summarize the current evidence for estrogen and, more generally, stroke in women, and to provide recommendations for future basic, preclinical, and clinical research studies. Conclusions— These studies may ultimately change the approach to stroke prevention and treatment in women.